Research Topics
| John S BradleySummaryAffiliation: Rady Children's Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Genetic structure of community acquired methicillin-resistant Staphylococcus aureus USA300Ryan Tewhey
Scripps Genomic Medicine, Scripps Translational Science Institute, La Jolla, CA, USA
BMC Genomics 13:508. 2012..The broad range of disease severity may be influenced by bacterial genetic variation...
Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse eventsJohn S Bradley
Rady Children s Hospital San Diego, San Diego, California 92123, USA
Pediatrics 123:e609-13. 2009..This report describes and summarizes the reported cases that led to safety concerns regarding the concurrent administration of intravenous ceftriaxone and calcium in this age group...- Unique considerations in the evaluation of antibacterials in clinical trials for pediatric community-acquired pneumoniaJohn S Bradley
Division of Pediatric Infectious Diseases, Rady Children s Hospital San Diego, San Diego, California 92123, USA
Clin Infect Dis 47:S241-8. 2008..Clinical trials that require invasive techniques for diagnosis and placebo-controlled randomized trials are not acceptable for children, who are considered to be a vulnerable population... - Considerations unique to pediatrics for clinical trial design in hospital-acquired pneumonia and ventilator-associated pneumoniaJohn S Bradley
Rady Children s Hospital San Diego, University of California, San Diego, USA
Clin Infect Dis 51:S136-43. 2010.... - Prevalence of hepatitis C virus antibody in newborn infants in southern California in 2003John S Bradley
Division of Infectious Diseases, Rady Children s Hospital San Diego, University of California at San Diego, San Diego, CA 92123, USA
Pediatr Infect Dis J 30:618-20. 2011..With advances in HCV antiviral therapy providing decreasing morbidity from chronic HCV infection, prenatal HCV screening to identify both mothers and at-risk infants should be reconsidered... - The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of AmericaJohn S Bradley
Department of Pediatrics, University of California San Diego School of Medicine and Rady Children s Hospital of San Diego, San Diego, California, USA
Clin Infect Dis 53:e25-76. 2011..Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted... - Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of AmericaJohn S Bradley
Department of Pediatrics, University of California San Diego School of Medicine and Rady Children s Hospital of San Diego, San Diego, California, USA
Clin Infect Dis 53:617-30. 2011..Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted... 
Pneumococcal endocarditis in childrenLaurence B Givner
Department of Pediatrics, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
Clin Infect Dis 38:1273-8. 2004..Pneumococcal endocarditis in children is unusual but often has serious complications...- Streptococcus pneumoniae infections in the neonateJill A Hoffman
Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
Pediatrics 112:1095-102. 2003..The aim of this study was to review the current epidemiology and clinical course of SPIN... - Comparative study of levofloxacin in the treatment of children with community-acquired pneumoniaJohn S Bradley
Children s Hospital and Health Center, San Diego, CA, USA
Pediatr Infect Dis J 26:868-78. 2007..Levofloxacin has established efficacy and safety in the treatment of community-acquired pneumonia (CAP) in adults, and its use as an alternative therapy for children with CAP has been proposed... - In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolidesEdward O Mason
Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
Antimicrob Agents Chemother 47:166-9. 2003..The ketolides appear to be active antimicrobials against penicillin- and macrolide-resistant pneumococci... - Pharmacodynamics and the prediction of efficacy in short-course antibiotic therapy: pediatric studies to validate the modelJohn S Bradley
Division of Infectious Diseases, Children s Hospital San Diego, San Diego, California 92123, USA
Pharmacotherapy 25:159S-164S. 2005..By using a mathematic model that integrates all important variables, one may be able to predict the probability of a cure with short-course therapy for each pathogen, antibiotic, site of infection, and host interaction... - Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USAMichael D Green
Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine. Pittsburgh, PA, USA
J Antimicrob Chemother 57:1240-3. 2006.... - Antibiotic stewardship in pediatrics: a necessityJohn S Bradley
Children's Hospital San Diego, University of California, San Diego, USA
Pediatr Infect Dis J 26:538-9. 2007 - Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonateJohn S Bradley
Division of Infectious Diseases, Children s Hospital and Health Center, San Diego, CA 92123, USA
Pediatr Infect Dis J 27:794-9. 2008..Hospitalized neonates are exposed to antibiotic-resistant bacterial pathogens and develop nosocomial infections. Limited data are available regarding the neonatal pharmacokinetics of meropenem, a broad spectrum carbapenem antibiotic... - Oral acyclovir suppression and neurodevelopment after neonatal herpesDavid W Kimberlin
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL 35233, USA
N Engl J Med 365:1284-92. 2011..Poor neurodevelopmental outcomes and recurrences of cutaneous lesions remain unacceptably frequent among survivors of neonatal herpes simplex virus (HSV) disease... - Guidelines for the selection of antibacterial therapy in childrenAlice L Pong
Children's Hospital and Health Center, 3020 Children's Way, MC 5041, San Diego, CA 92123, USA
Pediatr Clin North Am 52:869-94, viii. 2005..This article reviews factors important in the selection of antimicrobial agents in infants and children. Recommendations for antibiotic therapy for a wide range of infections occurring in children are provided... - Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of ageDavid W Kimberlin
Department of Pediatrics, University of Alabama, Birmingham, AL 35233, USA
Clin Infect Dis 50:221-8. 2010..Valacyclovir provides enhanced acyclovir bioavailability in adults, but limited data are available in children... - Clinical challenges of nosocomial infections caused by antibiotic-resistant pathogens in pediatricsAlice Pong
Division of Infectious Diseases, Children's Hospital and Health Center, San Diego, CA 92123, USA
Semin Pediatr Infect Dis 15:21-9. 2004..Nosocomial outbreaks caused by resistant organisms are described, and an approach to empiric therapy based on presumed pathogens, site of infection, and local resistance patterns is discussed... - Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenzaDavid W Kimberlin
Department of Pediatrics, University of Alabama at Birmingham, AL 35233, USA
J Infect Dis 207:709-20. 2013..Children <2 years of age are at high risk of influenza-related mortality and morbidity. However, the appropriate dose of oseltamivir for children <2 years of age is unknown... - Transmission of meropenem in breast milkJason B Sauberan
Department of Pharmacy, University of California, San Diego Medical Center and UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA
Pediatr Infect Dis J 31:832-4. 2012..18%. There were no dermatologic or gastrointestinal side effects noted in the breastfed infant. Meropenem appears to be acceptable to use during breast-feeding... - Old and new antibiotics for pediatric pneumoniaJohn S Bradley
University of California San Diego, School of Medicine, San Diego, CA, USA
Semin Respir Infect 17:57-64. 2002.... - Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccinesJohn S Bradley
Division of Infectious Diseases, Children's Hospital, San Diego, CA, USA
Pediatr Infect Dis J 21:592-8; discussion 613-4. 2002..pneumoniae. In contrast antibiotic regimens for life-threatening pulmonary infections in which Staphylococcus aureus is a suspected pathogen should include vancomycin... - Newer antistaphylococcal agentsJohn S Bradley
Division of Infectious Diseases, Children s Hospital San Diego, San Diego, California 92123, USA
Curr Opin Pediatr 17:71-7. 2005.... - A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritisROBERT TRACY BALLOCK
Rady Children s Hospital, San Diego, California, USA
J Pediatr Orthop 29:636-42. 2009.... - Safety of oseltamivir compared with the adamantanes in children less than 12 months of ageDavid W Kimberlin
Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alabama, Birmingham, Birmingham, AL 35233, USA
Pediatr Infect Dis J 29:195-8. 2010..To assess potential neurologic adverse effects of oseltamivir use in infants, a retrospective chart review was performed in infants less than 12 months of age who received oseltamivir, amantadine, or rimantadine... - Invasive pneumococcal infections in children with aspleniaGordon E Schutze
Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, USA
Pediatr Infect Dis J 21:278-82. 2002..Asplenia is associated with an increased risk of infections caused by Streptococcus pneumoniae. Overwhelming infection can be fulminate and lead to a fatal outcome... - Pharmacokinetics of gatifloxacin in infants and childrenEdmund V Capparelli
Pediatric Pharmacology Research Unit, University of California, San Diego, California, USA
Antimicrob Agents Chemother 49:1106-12. 2005..h/ml (estimated free AUC/MIC ratio of > or =34 for MIC of < or =0.5 microg/ml). These data suggest that gatifloxacin at a dose of 10 mg/kg every 24 h will achieve therapeutic concentrations in plasma in infants and children... - Prediction of neurologic sequelae in childhood tuberculous meningitis: a review of 20 cases and proposal of a novel scoring systemAkihiko Saitoh
Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, CA, USA
Pediatr Infect Dis J 24:207-12. 2005..CONCLUSIONS: The TBAN score is an objective marker for predicting severe NS in children with TBM... - New antibiotics for Gram-positive infectionsJohn S Bradley
Division of Infectious Diseases, Children's Hospital, San Diego, CA 92123, USA
Adv Exp Med Biol 582:151-65. 2006 - Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trialsBrad Spellberg
Division of Infectious Diseases, Harbor University of California at Los Angeles Medical Center, Torrance, California 90502, USA
Clin Infect Dis 49:383-91. 2009..In the absence of placebo-controlled trials, we sought to define the magnitude of efficacy of antimicrobial agents and resulting noninferiority margins for studies of complicated skin and skin-structure infection (SSSI)...